Isolation and Characterization of Anti-FcgammaRIII (CD16) Llama Single-domain Antibodies That Activate Natural Killer Cells
Overview
Biotechnology
Authors
Affiliations
FcgammaRIII (CD16) plays an important role in the anti-tumor effects of therapeutic antibodies. Bi-specific antibodies (bsAbs) targeting FcgammaRIII represent a powerful alternative to the recruitment of the receptor via the Fc fragment, but are not efficiently produced. Single-domain antibodies (sdAbs) endowed with many valuable structural features might help to bypass this problem. In the present work, we have isolated anti-FcgammaRIII sdAbs (C21 and C28) from a phage library generated from a llama immunized with FcgammaRIIIB extra-cellular domains. These sdAbs bind FcgammaRIIIA+ NK cells and FcgammaRIIIB+ polymorphonuclear cells, but not FcgammaRI+ or FcgammaRII+ cells, as detected by indirect immunofluorescence. Competition experiments showed that C21 and C28 sdAbs bind different FcgammaRIII epitopes, with C21 recognizing a linear and C28 a conformational epitope of the receptor. Surface plasmon resonance experiments showed that C21 and C28 sdAbs bind FcgammaRIII with a K(D) in the 10 and 80 nM range, respectively. Importantly, the engagement by both molecules of FcgammaRIIIA expressed by transfected Jurkat T cells or by NK cells derived from peripheral blood induced a strong IL-2 and IFN-gamma production, respectively. These anti-FcgammaRIII sdAbs represent versatile tools for generating bsAbs under various formats, able to recruit FcgammaRIII killer cells to target and destroy tumor cells.
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.
Ghemrawi R, Abuamer L, Kremesh S, Hussien G, Ahmed R, Mousa W Biomedicines. 2024; 12(9).
PMID: 39335671 PMC: 11429153. DOI: 10.3390/biomedicines12092158.
Enhancing Anti-Cancer Immune Response by Acidosis-Sensitive Nanobody Display.
Knepper L, Ankrom E, Thevenin D J Membr Biol. 2024; 257(5-6):391-401.
PMID: 39254684 PMC: 11584308. DOI: 10.1007/s00232-024-00322-3.
Cao L, Yu B, Klauser P, Zhang P, Li S, Wang L Angew Chem Int Ed Engl. 2024; 63(47):e202412843.
PMID: 39113386 PMC: 11560669. DOI: 10.1002/anie.202412843.
Tri-specific killer engager: unleashing multi-synergic power against cancer.
Winidmanokul P, Panya A, Okada S Explor Target Antitumor Ther. 2024; 5(2):432-448.
PMID: 38745768 PMC: 11090690. DOI: 10.37349/etat.2024.00227.
Wang Y, Zou X, Guo X, Zhang Z, Wang M, Hung T Genes (Basel). 2024; 15(4).
PMID: 38674401 PMC: 11049955. DOI: 10.3390/genes15040467.